Rocket Watch 02 - 03Dec2024Watch out for this stock in December. Potential to explode. 100% upside possible
Note: This is not a recommendation or investment advice, just a stock to watch. Do your own research.
REVB trade ideas
Another Interesting Setup | Dollar Cost Average InRevelation Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. The company engages in developing therapeutic product candidates, including REVTx-99b that is in a Phase Ib clinical trial for the prevention or treatment of chronic nasal congestion and allergic rhinitis; and REVTx-200, a nonclinical stage product for intranasal therapy. It is also involved in developing REVTx-300, a non-clinical stage product that is being developed as a potential therapy for the treatment of chronic organ disease, including chronic kidney disease and non-alcoholic steatohepatitis; and REVDx-501, a rapid test kit, which is a point of care in vitro diagnostic test that has the potential to detect respiratory viral infections, such as SARS-CoV-2, Influenza A, Influenza B, parainfluenza, or respiratory syncytial virus. The company was founded in 2020 and is based in San Diego, California.
REVB REVERSAL REVB had seen 90% drop in 4 months. With breakout on the technicals, the daily could see a test top the LEADING A IC. If the LEADING B is even thought about, that will be close to testing the entire gapfill
BREAKTHROUGH ON REVB This stock has a few factors that lead me to believe it could make a move to the $3 judging by chart indicators.
It has been testing the BOLL and IC on the 1min and 4hour since the 15th of March.
On the daily it has broken through base IC and what is next would be the upper BOLL. What could make this happen is the MACD cross. The MACD has crossed on the 240 and is super close to getting there on the 1D. If the MACD crossed and wanted to continue. That will lead price action to test the leading IC which could be around $3
This stock -90% in 4 monthsThis stock has seem a dramatic drop in price since January. It went from $11 all the way down to $1. Lately we seen what look to be a floor. With a positive view on the market recent it’s possible we could see upward movement coming from REVB. If this stock even think about going back to IPO levels that would be close to a 10x. If this stock even hits $3 there nothing really stopping it all the way to $8.
We are seeing a lot of testing in critical price action for the chart also the IC and BOLL.
Right now it’s it testing the BOLL on the daily but if this stock breaks through it and test the leading IC. That lines up with that $3 mark. And after that is IPO levels.
REVB Reasons Not To Trade, Reasons to TradeThis chart is a great example of a gamble. Looking to the left, we see huge potential to return where it came from but the 40% gain today comes from no information. Nothing is driving the increase. We don't see market maker levels of volume either. They may have entered a few weeks ago on the 23rd, but that could also be a huge short position. We don't know what the volume was. If this stock ends up having news, it may run up fast, with a float of only 8 million. I don't really like anything below the 200 moving average though, so we lose that differential if we wait until the cross over. I just don't think the gamble is worth it.
$REVBRevelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.
